Phase II study of DHP107 (oral paclitaxel) in the first-line treatment of HER2-negative recurrent or metastatic breast cancer (OPTIMAL study)

BACKGROUND: Standard intravenous (IV) paclitaxel is associated with hypersensitivity/toxicity. Alternative IV formulations have improved tolerability but still require frequent hospital visits and IV infusion. DHP107 is a novel oral formulation of paclitaxel that is approved in South Korea for the t...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Sung-Bae, Seo, Jae Hong, Ahn, Jin-Hee, Kim, Tae-Yong, Kang, Seok Yun, Sohn, Joohyuk, Yang, Yaewon, Park, Kyong Hwa, Moon, Yong Wha, Lim, Seungtaek, Kang, Myoung Joo, Yoon, Koung Eun, Cho, Hyun Ju, Lee, Keun Seok
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8679020/
https://www.ncbi.nlm.nih.gov/pubmed/34925553
http://dx.doi.org/10.1177/17588359211061989

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8679020/
https://www.ncbi.nlm.nih.gov/pubmed/34925553
http://dx.doi.org/10.1177/17588359211061989

Ejemplares similares